Asia Pacific Dialysis Market value was valued over USD 23.0 billion in 2019 and is expected to witness 4.5% CAGR from 2019 to 2026.
Get more details on this report - Request Free Sample PDF
Incidence and prevalence of chronic kidney failure and the resulting need for renal replacement therapies is rapidly increasing in Asia Pacific. Rising number of infections such as bacterial, mycobacterial, hepatitis B, among others further account to the market growth. According to the International Society of Nephrology, the mortality rate of acute kidney injury infections contributes approximately 52% in the Asia Pacific region, thus driving the dialysis market.
Growth opportunities tapped by market players in the region also contribute to propel the market growth. For instance, Medtronic Inc. of Minnesota entered the kidney dialysis business in collaboration with India’s Apollo Hospitals Enterprise Ltd. Patients in the developing countries, are less likely to have access to high-end services; and need options that don’t require as much water and infrastructure. Medtronic is developing a low-cost, portable approach for such patients in developing economies. Furthermore, factors such as rise in independent dialysis centres, growing awareness about dialysis treatment modalities as well as reimbursement changes and healthcare insurance policies will boost the dialysis product and services business growth in the Asia Pacific region.
Asia Pacific Market Share, By Type
Haemodialysis segment will account for the largest market size USD28,294.0 million in 2026. Rising prevalence of chronic diseases among geriatric population significantly impacts the market growth. Also, emerging economies such as India and China have high incidence of obesity and diabetes. Additionally, by 2040, 123 million Indians will suffer from diabetes that will also increase the occurrence of renal diseases flourishing segmental growth in forthcoming years.
Asia Pacific Market Size, By Product & Services
The services segment will account the largest market growth during the forecasting period to reach 24,958.8 million in 2026. Significant revenue size is attributed to the increasing adoption of home haemodialysis and peritoneal dialysis, availability of advanced healthcare facilities coupled with high healthcare expenditure.
Asia Pacific Market Trends, By End-use
The in-centre dialysis segment will account the largest market growth during the forecasting period to reach 22,478.0 million in 2026 in the Asia Pacific region. High segment growth is attributed to rising prevalence of renal failure in the region, and improved treatment efficiency by the two ways in which the treatment can be done. These treatments include standard in-centre dialysis that is done 3-5 times thrice a week and nocturnal haemodialysis that is done for 8 hours at night.
Asia Pacific Market Foreast, By Country
Japan dialysis market recorded approximately USD 6,200.8 million revenue size in 2019. Improving healthcare infrastructure and supportive government initiatives will drive the dialysis market in the country. Furthermore, increasing geriatric population and rising adoption of home haemodialysis and peritoneal dialysis will also contribute to market growth.
Competitive Market Share
Some of the major industry players involved in Asia Pacific dialysis market include Asahi Kasei Corporation, Baxter International Inc., B Braun Melsungen AG, Fresenius Medical Care, among others. These companies are undertaking various strategic initiatives such as acquisitions, merger and collaborations that have helped them to sustain in the market. For instance, in May 2018, Asahi Kasei Corporation and NxStage announced their strategic business alliance for establishing partnership with leading renal product manufacturing companies in Asia. The strategic alliance will enhance company’s business revenue.
The first historical dialysis procedure was conducted in 1913 by Abel, Rowntree, and Turner. They dialyzed anesthetized animals by directing their blood through tubes outside the body. Initially hirudin was used as an anticoagulant for dialysis treatments, however since 1937, heparin was adopted as a necessary coagulant and is continued till present day. The western and Asian countries provide end-stage renal disease patients a full access to haemodialysis. However, the South and South-east Asian countries provide access to only a limited fraction of the patients. Although the cost of haemodialysis is much lower compared to western countries, the patient cannot afford the cost that are not covered in health insurance. However, growing inclination towards dialysis as an alternative to kidney transplantation will offer several growth opportunities in the foreseeable future.